BioSpace News Archive

The WHO says that oral diseases are the fourth-most expensive disease to treat across the world. Therefore, oral health maintenance expenditure is a huge healthcare concern impacting both developed and developing countries.

SIGA Technologies, Inc. announced that it will host its 2020 Annual Meeting of Stockholders as a virtual-only meeting that will be held via live audio webcast due to the public health and safety concerns related to the COVID-19 pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees, and others.

BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the following upcoming investor conferences:

Sumitovant Biopharma Ltd. announced today that Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, and one of five healthcare companies in the Sumitovant family of companies, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its once-daily relugolix combination tablet (relugolix 40 mg,

Braeburn announces that it has requested final approval from the U.S. Food and Drug Administration (FDA) of the New Drug Application for BRIXADI™ (buprenorphine) weekly and monthly extended-release injection for the treatment of opioid use disorder (OUD). Once approved, BRIXADI

MedX Health Corp. is pleased to announce that it is implementing an online marketing and awareness program through AGORACOM.

Camurus AB (NASDAQ: CAMX) (STO: CAMX) today announces that the company’s US partner Braeburn has submitted a request for final approval of Brixadi™ (buprenorphine) weekly and monthly extended release injection for the treatment of opioid use disorder to the US Food and Drug Administration (FDA).

AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the purchase of a state-of-the-art commercial manufacturing facility in Boulder, Colorado U.S.A.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces the preliminary results of the Phase 1a clinical study